Showing posts with label The Scripps Research Institute. Show all posts
Showing posts with label The Scripps Research Institute. Show all posts

Sunday, October 27, 2013

New Approach to Treating Eye Disease

"Researchers have revealed a new approach for treating human eye disease that has proved to be successful in preclinical studies. This is according to a study published in the Journal of Clinical Investigation," according to a Medical News Today post. "The research team from The Scripps Research Institute (TSRI) in California, Mount Sinai Hospital in Canada and the University of California, San Diego (UCSD), say their findings could lead to new treatments to prevent blindness. Many types of blindness, including diabetic retinopathy and macular degeneration, can be linked to the abnormal growth of blood vessels (neovascularization) in the retina at the back of the eye, the researchers explain. The retina is a thin layer of soft tissue consisting of blood vessels and light-sensing cells." Read more.

Wednesday, October 23, 2013

Technique for Treating Eye Diseases Effective in Preclinical Studies

“A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute (TSRI) in La Jolla, California,” according to Science Daily. “The studies involved controlling the actions of microRNAs, tiny pieces of RNA that were once considered to be "junk" but are now known to fine-tune gene activation and expression. The researchers showed that treating mice with short RNA strands that precisely target and inhibit microRNAs (antimicroRNAs) can stop the aberrant growth of blood vessels (neovascularization). It is this abnormal proliferation of vessels that exacerbates vision loss in neovascular eye diseases like wet macular degeneration and diabetic retinopathy, two of the leading causes of blindness. Described in the cover story of the November issue of the Journal of Clinical Investigation, the microRNA treatments blocked aberrant vessel growth without damaging existing vasculature or neurons in three separate models of neovascular eye disease -- a proof-of-principle that suggests future treatment based on the same approach may be effective in humans.” Read more.